VioQuest doses first patient in VQD-002 trial for leukemia

By Lisa Kerner

Charlotte, N.C., Sept. 12 - VioQuest Pharmaceuticals, Inc. dosed the first patient in its phase 1/2a clinical trial of VQD-002 (triciribine-phosphate or TCN-P) in leukemia.

VQD-002 targets Akt, also know as Protein Kinase B, which is over-activated in a high percentage of leukemia tumors and solid tumors, including breast, ovarian, colorectal and pancreatic cancers.

VioQuest is a biopharmaceutical company located in Basking Ridge, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.